Dr. Braun On Frontline Immunotherapy In Advanced Rcc

Dr. Braun on Frontline Immunotherapy in Advanced RCC

Dr. Braun on Evolution of Immunotherapy in Advanced Renal Cell Carcinoma

Braun, ImmunoUPDATED

Frontline Treatment Approaches in Advanced RCC

Dr. Choueiri on Frontline Trials of Immunotherapy in RCC

Dr. Rana McKay on Frontline Immunotherapy for Metastatic RCC

GU Oncology Now

Dr. Van Veldhuizen on Frontline Immunotherapy for Kidney Cancer

Updated Results of a Clinical Trial Evaluating Pembrolizumab + Axitinib for Frontline Adv RCC

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

PeerView Oncology

Immunotherapy Combinations Improve Survival in Advanced Renal Cell Carcinoma

Targeted Oncology

Front-line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced RCC

Metastatic RCC: Using Frontline Ipilimumab/Nivolumab

Dr. Amin on Next Steps With Immunotherapy in Advanced RCC

Dr. Jonasch on Single-Agent Pembrolizumab in Non-Clear Cell RCC

10.19.20 Urology COViD Didactics - Treating Metastatic Renal Cell Carcinoma

Urology Residents

David Braun, MD, PhD, shares how the treatment of ccRCC in the refractory setting is changing

Dr. Powles on FDA Approval of Pembrolizumab Plus Axitinib in Advanced RCC

Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC

The Uromigos: Frontline Therapy in RCC

GU Oncology Now

Dr. Tykodi on the KEYNOTE-427 Trial With Pembrolizumab in RCC